KNSA FY 2022 Earnings — Kiniksa Pharmaceuticals, Ltd. Revenue & Financial Results | Market Cap Arena

KNSAKiniksa Pharmaceuticals, Ltd.

$3B

FY 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$220M+471.2% YoY

Gross Profit

$197M89.6% margin

Operating Income

$10M4.4% margin

Net Income

$183M83.3% margin

EPS (Diluted)

$2.60

Cash Flow

Operating Cash Flow

$6M

Free Cash Flow

$6M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$460M

Total Liabilities

$64M

Stockholders' Equity

$396M

Cash & Equivalents

$123M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$220M	$39M	+471.2%
Gross Profit	$197M	$29M	+570.0%
Operating Income	$10M	-$157M	+106.2%
Net Income	$183M	-$158M	+216.1%